Stock listing
1GDA Stock Price, News, Filings & Events — Zevra Therapeutics, Inc.
Selected listing: 1GDA · TRADEGATE · EUR · DE
This page tracks Zevra Therapeutics, Inc.'s 1GDA:TRADEGATE listing on TRADEGATE in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 1GDA:TRADEGATE. 1GDA:TRADEGATE is the stock-level entry point for investors researching Zevra Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- 1GDA:TRADEGATE
- Asset type
- Stock
- Market cap
- $704.9M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- TRADEGATE
- Currency
- EUR
Zevra Therapeutics, Inc. 1GDA:TRADEGATE stock context
This page tracks Zevra Therapeutics, Inc.'s 1GDA:TRADEGATE listing on TRADEGATE in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 1GDA:TRADEGATE. 1GDA:TRADEGATE is the stock-level entry point for investors researching Zevra Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Zevra Therapeutics, Inc.
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Sy...
August 25, 2026
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
August 5, 2026
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
August 4, 2026
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) i...
August 3, 2026
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the...
July 24, 2026
Research Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for 1GDA:TRADEGATE.
Zevra Therapeutics, Inc. company profile
View the public company page for Zevra Therapeutics, Inc. on 6ix.
Zevra Therapeutics, Inc. news
Read company news and market updates connected to Zevra Therapeutics, Inc..
Zevra Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Zevra Therapeutics, Inc..
Alternate listings
ZVRA:NASDAQ
US · USD
Alternate listing for Zevra Therapeutics, Inc.; the primary context on this page is 1GDA:TRADEGATE.
1GDA:GETTEX
DE · EUR
Alternate listing for Zevra Therapeutics, Inc.; the primary context on this page is 1GDA:TRADEGATE.
ZVRA:BOATS
US · USD
Alternate listing for Zevra Therapeutics, Inc.; the primary context on this page is 1GDA:TRADEGATE.
A2QLX7:LSX
DE · EUR
Alternate listing for Zevra Therapeutics, Inc.; the primary context on this page is 1GDA:TRADEGATE.
A2QLX7:LS
DE · EUR
Alternate listing for Zevra Therapeutics, Inc.; the primary context on this page is 1GDA:TRADEGATE.
1GDA:SWB
DE · EUR
Alternate listing for Zevra Therapeutics, Inc.; the primary context on this page is 1GDA:TRADEGATE.
1GDA:FWB
DE · EUR
Alternate listing for Zevra Therapeutics, Inc.; the primary context on this page is 1GDA:TRADEGATE.
1GDA:DUS
DE · EUR
Alternate listing for Zevra Therapeutics, Inc.; the primary context on this page is 1GDA:TRADEGATE.
1GDA:HAM
DE · EUR
Alternate listing for Zevra Therapeutics, Inc.; the primary context on this page is 1GDA:TRADEGATE.
1GDA:MUN
DE · EUR
Alternate listing for Zevra Therapeutics, Inc.; the primary context on this page is 1GDA:TRADEGATE.